Product
NI006
1 clinical trial
1 indication
Indication
Amyloid Transthyretin CardiomyopathyClinical trial
A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label ExtensionStatus: Completed, Estimated PCD: 2023-07-26